Literature DB >> 17686853

No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys.

Norman L Letvin1, Srini S Rao, Vi Dang, Adam P Buzby, Birgit Korioth-Schmitz, Dilani Dombagoda, Jenny G Parvani, Ryon H Clarke, Liat Bar, Kevin R Carlson, Pamela A Kozlowski, Vanessa M Hirsch, John R Mascola, Gary J Nabel.   

Abstract

Defining the immune correlates of the protection against human immunodeficiency virus type 1 (HIV-1) acquisition in individuals who are exposed to HIV-1 but do not become infected may provide important direction for the creation of an HIV-1 vaccine. We have employed the simian immunodeficiency virus (SIV)/rhesus monkey model to determine whether monkeys can be repeatedly exposed to a primate lentivirus by a mucosal route and escape infection and whether virus-specific immune correlates of protection from infection can be identified in uninfected monkeys. Five of 18 rhesus monkeys exposed 18 times by intrarectal inoculation to SIVmac251 or SIVsmE660 were resistant to infection, indicating that the exposed/uninfected phenotype can be reproduced in a nonhuman primate AIDS model. However, routine peripheral blood lymphocyte gamma interferon enzyme-linked immunospot (ELISPOT), tetramer, and intracellular cytokine staining assays, as well as cytokine-augmented ELISPOT and peptide-stimulated tetramer assays, failed to define a systemic antigen-specific cellular immune correlate to this protection. Further, local cell-mediated immunity could not be demonstrated by tetramer assays of these protected monkeys, and local humoral immunity was not associated with protection against acquisition of virus in another cohort of mucosally exposed monkeys. Therefore, resistance to mucosal infection in these monkeys may not be mediated by adaptive virus-specific immune mechanisms. Rather, innate immune mechanisms or an intact epithelial barrier may be responsible for protection against mucosal infection in this population of monkeys.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17686853      PMCID: PMC2169024          DOI: 10.1128/JVI.00822-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses.

Authors:  R Kaul; S L Rowland-Jones; J Kimani; T Dong; H B Yang; P Kiama; T Rostron; E Njagi; J J Bwayo; K S MacDonald; A J McMichael; F A Plummer
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

2.  HIV versus the immune system: another apparent victory for the virus.

Authors:  N L Letvin; B D Walker
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

3.  CD4+ T cell responses in HIV-exposed seronegative women are qualitatively distinct from those in HIV-infected women.

Authors:  Judie B Alimonti; Sandra A Koesters; Joshua Kimani; Lucy Matu; Charles Wachihi; Francis A Plummer; Keith R Fowke
Journal:  J Infect Dis       Date:  2004-12-01       Impact factor: 5.226

4.  HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi.

Authors:  R Kaul; F A Plummer; J Kimani; T Dong; P Kiama; T Rostron; E Njagi; K S MacDonald; J J Bwayo; A J McMichael; S L Rowland-Jones
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

5.  HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers.

Authors:  R Kaul; D Trabattoni; J J Bwayo; D Arienti; A Zagliani; F M Mwangi; C Kariuki; E N Ngugi; K S MacDonald; T B Ball; M Clerici; F A Plummer
Journal:  AIDS       Date:  1999-01-14       Impact factor: 4.177

6.  Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons.

Authors:  S Mazzoli; L Lopalco; A Salvi; D Trabattoni; S Lo Caputo; F Semplici; M Biasin; C Bl; A Cosma; C Pastori; F Meacci; F Mazzotta; M L Villa; A G Siccardi; M Clerici
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

7.  Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques.

Authors:  J L Greenier; C J Miller; D Lu; P J Dailey; F X Lü; K J Kunstman; S M Wolinsky; M L Marthas
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

8.  Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions.

Authors:  S W Wang; P A Kozlowski; G Schmelz; K Manson; M S Wyand; R Glickman; D Montefiori; J D Lifson; R P Johnson; M R Neutra; A Aldovini
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

9.  Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer.

Authors:  A Seth; I Ourmanov; M J Kuroda; J E Schmitz; M W Carroll; L S Wyatt; B Moss; M A Forman; V M Hirsch; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

10.  Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex.

Authors:  M J Kuroda; J E Schmitz; D H Barouch; A Craiu; T M Allen; A Sette; D I Watkins; M A Forman; N L Letvin
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

View more
  41 in total

1.  Genetic immunization in the lung induces potent local and systemic immune responses.

Authors:  Kaimei Song; Diane L Bolton; Chih-Jen Wei; Robert L Wilson; Jeremy V Camp; Saran Bao; Joseph J Mattapallil; Leonore A Herzenberg; Leonard A Herzenberg; Charla A Andrews; Jerald C Sadoff; Jaap Goudsmit; Maria Grazia Pau; Robert A Seder; Pamela A Kozlowski; Gary J Nabel; Mario Roederer; Srinivas S Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-06       Impact factor: 11.205

2.  Mucosal simian immunodeficiency virus transmission in African green monkeys: susceptibility to infection is proportional to target cell availability at mucosal sites.

Authors:  Ivona Pandrea; Nicholas F Parrish; Kevin Raehtz; Thaidra Gaufin; Hannah J Barbian; Dongzhu Ma; Jan Kristoff; Rajeev Gautam; Fang Zhong; George S Haret-Richter; Anita Trichel; George M Shaw; Beatrice H Hahn; Cristian Apetrei
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level.

Authors:  A L Erickson; C B Willberg; V McMahan; A Liu; S P Buchbinder; L A Grohskopf; R M Grant; D F Nixon
Journal:  Clin Vaccine Immunol       Date:  2008-09-24

4.  Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.

Authors:  Matthew R Reynolds; Andrea M Weiler; Shari M Piaskowski; Holly L Kolar; Ann J Hessell; Madelyn Weiker; Kim L Weisgrau; Enrique J León; W Eric Rogers; Robert Makowsky; Adrian B McDermott; Rosanne Boyle; Nancy A Wilson; David B Allison; Dennis R Burton; Wayne C Koff; David I Watkins
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

5.  Short communication: Viremic control is independent of repeated low-dose SHIVSF162p3 exposures.

Authors:  Tara R Henning; Debra Hanson; Sundaram A Vishwanathan; Katherine Butler; Charles Dobard; Gerardo Garcia-Lerma; Jessica Radzio; James Smith; Janet M McNicholl; Ellen N Kersh
Journal:  AIDS Res Hum Retroviruses       Date:  2014-10-14       Impact factor: 2.205

6.  Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.

Authors:  Monica Vaccari; Brandon F Keele; Steven E Bosinger; Melvin N Doster; Zhong-Min Ma; Justin Pollara; Anna Hryniewicz; Guido Ferrari; Yongjun Guan; Donald N Forthal; David Venzon; Claudio Fenizia; Tia Morgan; David Montefiori; Jeffrey D Lifson; Chris J Miller; Guido Silvestri; Margherita Rosati; Barbara K Felber; George N Pavlakis; James Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

7.  Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.

Authors:  Milan Raska; Kazuo Takahashi; Lydie Czernekova; Katerina Zachova; Stacy Hall; Zina Moldoveanu; Matt C Elliott; Landon Wilson; Rhubell Brown; Dagmar Jancova; Stephen Barnes; Jana Vrbkova; Milan Tomana; Phillip D Smith; Jiri Mestecky; Matthew B Renfrow; Jan Novak
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

8.  Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.

Authors:  Scott G Hansen; Cassandra Vieville; Nathan Whizin; Lia Coyne-Johnson; Don C Siess; Derek D Drummond; Alfred W Legasse; Michael K Axthelm; Kelli Oswald; Charles M Trubey; Michael Piatak; Jeffrey D Lifson; Jay A Nelson; Michael A Jarvis; Louis J Picker
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

9.  Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells.

Authors:  David Verhoeven; Sumathi Sankaran; Melanie Silvey; Satya Dandekar
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

10.  Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.

Authors:  Brandon F Keele; Hui Li; Gerald H Learn; Peter Hraber; Elena E Giorgi; Truman Grayson; Chuanxi Sun; Yalu Chen; Wendy W Yeh; Norman L Letvin; John R Mascola; Gary J Nabel; Barton F Haynes; Tanmoy Bhattacharya; Alan S Perelson; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.